Neuroendocrine carcinoma
MONDO:0002120A malignant neuroendocrine neoplasm composed of cells containing secretory granules that stain positive for NSE and chromogranin. The neoplastic cells are often round and form clusters or trabecular sheets. Representative examples are small cell carcinoma, large cell neuroendocrine carcinoma, and Merkel cell carcinoma.
Also known as: NEC, neuroendocrine cancer, neuroendocrine carcinoma
3436 clinical trials for this condition and its sub-types, 106 tagged with Neuroendocrine carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Neuroendocrine carcinoma
-
Small cell carcinoma 26 trials · 542 incl. sub-types
18 sub-types
- Small cell lung carcinoma 514 trials · 515 incl. sub-types Sub-types →
- Prostate small cell carcinoma 9 trials
- Urinary bladder small cell neuroendocrine carcinoma 9 trials
- Cervical small cell carcinoma 4 trials
- Esophageal small cell neuroendocrine carcinoma 2 trials
- Ovarian small cell carcinoma 1 trial · 2 incl. sub-types Sub-types →
- Ureter small cell carcinoma 1 trial
- Bartholin gland small cell carcinoma 0 trials
- Ampulla of vater small cell neuroendocrine carcinoma 0 trials
- Colon small cell neuroendocrine carcinoma 0 trials
- Endometrial small cell carcinoma 0 trials
- Extrahepatic bile duct small cell adenocarcinoma 0 trials
- Gallbladder small cell neuroendocrine carcinoma 0 trials
- Gastric small cell neuroendocrine carcinoma 0 trials
- Laryngeal small cell carcinoma 0 trials
- Pancreatic small cell neuroendocrine carcinoma 0 trials
- Salivary gland small cell carcinoma 0 trials
- Thymus small cell carcinoma 0 trials
-
Cutaneous neuroendocrine carcinoma 78 trials
-
Medullary thyroid gland carcinoma 42 trials · 53 incl. sub-types
1 sub-type
- Familial medullary thyroid carcinoma 23 trials
-
Large cell neuroendocrine carcinoma 12 trials · 31 incl. sub-types
6 sub-types
- Pulmonary large cell neuroendocrine carcinoma 20 trials Sub-types →
- Cervical large cell neuroendocrine carcinoma 4 trials
- Breast large cell neuroendocrine carcinoma 0 trials
- Ovarian large-cell neuroendocrine carcinoma 0 trials
- Pancreatic large cell neuroendocrine carcinoma 0 trials
- Thymic large cell neuroendocrine carcinoma 0 trials
-
Pancreatic endocrine carcinoma 12 trials
2 sub-types
-
Malignant adrenal gland pheochromocytoma 11 trials
-
Liver neuroendocrine carcinoma 3 trials
2 sub-types
-
Thymic neuroendocrine carcinoma 3 trials
5 sub-types
-
Goblet cell carcinoma 2 trials
-
1 sub-type
-
Combined lung carcinoma 0 trials · 1 incl. sub-types
2 sub-types
-
Vulvar neuroendocrine carcinoma 0 trials
1 sub-type
- Bartholin gland small cell carcinoma 0 trials
Most studied deeper sub-types
-
Engineered immune cells take aim at deadly lung cancer
Disease control Not yet recruitingThis early-phase trial tests a new therapy for people with advanced small cell lung cancer or similar neuroendocrine cancers that have not responded to prior treatment. The approach involves collecting a patient's own immune cells, modifying them in a lab to recognize a protein c…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 18:00 UTC
-
Can a new drug boost chemotherapy for a rare cancer?
Disease control Not yet recruitingThis phase III trial is testing whether adding an experimental drug called LBL-024 to standard chemotherapy can help people with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC), a rare and aggressive cancer. Participants will receive either LBL-024 or a placebo alongsid…
Phase 3 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug cocktail aims to tame rare lung cancer
Disease control Not yet recruitingThis study tests whether adding a new drug, obrixtamig, to standard chemotherapy can help people with a rare and aggressive lung cancer called large-cell neuroendocrine carcinoma (LCNEC). The trial will include 75 adults with advanced LCNEC that cannot be cured by surgery. Resear…
Phase 2 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a Two-Drug chemo combo outsmart resistant tumors?
Disease control Not yet recruitingThis early-stage trial is testing whether combining two chemotherapy drugs—liposomal irinotecan and cisplatin—can safely shrink or control advanced solid tumors that have not responded to standard treatments. The study will enroll about 44 adults aged 20 to 85 with various types …
Phase 1 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New radiation drug targets tough cancers in early trial
Disease control Not yet recruitingThis early study tests a new drug (177Lu-DTPA-SC16.56) that delivers radiation directly to cancer cells in people with small-cell lung cancer or neuroendocrine prostate cancer that has come back after standard chemotherapy. The main goal is to find the safest dose and see if the …
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a Triple-Drug combo outsmart a rare and aggressive cancer?
Disease control Not yet recruitingThis clinical trial is testing whether adding two newer drugs—QL1706 and lenvatinib—to standard chemotherapy can help people with a rare and aggressive cancer called extrapulmonary neuroendocrine carcinoma (EP-NEC). The study will compare the combination against chemotherapy alon…
Phase 2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Experimental combo aims to tackle Treatment-Resistant cancers
Disease control Not yet recruitingThis early-stage trial tests whether an experimental drug called TLN-499, combined with the approved cancer drug venetoclax, is safe and tolerable for people with certain advanced solid tumors that have stopped responding to standard treatments. The study includes adults with sma…
Phase 1 • Sponsor: Treeline Biosciences, Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat gut tumors
Disease control Not yet recruitingThis phase 2 trial tests a new drug called ivonescimab (AK112) combined with chemotherapy (irinotecan and cisplatin) for people with metastatic digestive system neuroendocrine cancer that has spread. Some participants also receive a procedure called TACE, which blocks blood flow …
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Experimental drug targets Hard-to-Treat neuroendocrine cancers
Disease control Not yet recruitingThis trial tests an experimental drug called CTX-471 in people with advanced neuroendocrine tumors that have a specific marker (NCAM) and have stopped responding to standard treatments. Participants receive the drug by IV every two weeks. The study aims to see if the drug can shr…
Phase 2 • Sponsor: Compass Therapeutics • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug ZG006 takes on chemo in advanced cancer battle
Disease control Not yet recruitingThis study tests a new drug called ZG006 against standard chemotherapy for people with advanced neuroendocrine carcinoma, a type of cancer. About 240 adults who have already had other treatments will be randomly assigned to receive either ZG006 or a chemotherapy chosen by their d…
Phase 3 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Experimental drug SHR-A1904 takes on rare cancer
Disease control Not yet recruitingThis phase II trial tests an experimental drug called SHR-A1904 in 23 people with advanced neuroendocrine carcinoma whose cancer has worsened after standard chemotherapy. The study measures how many patients have their tumors shrink or disappear, how long they live without the ca…
Phase 2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Triple-Drug cocktail takes aim at rare, aggressive cancers
Disease control Not yet recruitingThis phase 2 trial tests a combination of three drugs—benmelstobart (an immunotherapy), anlotinib (a targeted therapy), and standard chemotherapy—as a first treatment for people with large-cell neuroendocrine carcinoma of the lung or similar cancers outside the lung. The study ai…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Promising new combo aims to extend life in rare, Tough-to-Treat cancer
Disease control Not yet recruitingThis study tests whether adding two immunotherapy drugs (zimberelimab and domvanalimab) to standard chemotherapy (FOLFIRI) helps people with a rare, fast-growing neuroendocrine cancer live longer. About 122 adults whose cancer has worsened after first treatment will take part. Th…
Phase 2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Triple-Drug cocktail aims to tackle rare cancer
Disease control Not yet recruitingThis phase 2 trial tests a combination of three drugs—sintilimab, surufatinib, and temozolomide—in 32 people with advanced neuroendocrine carcinoma that has worsened after prior treatment. The goal is to see if the combination can shrink tumors and control the disease. Participan…
Phase 2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 26, 2026 13:43 UTC
-
New device could help save preterm babies by spotting oxygen drops
Diagnosis Not yet recruitingThis study tests a new light-based monitor (NIRS) that checks oxygen levels in the abdomen of preterm infants. Researchers want to see if it works reliably and safely on 50 babies born before 35 weeks. If it does, it could help doctors quickly detect life-threatening gut problems…
Sponsor: Carag AG • Aim: Diagnosis
Last updated Jun 27, 2026 08:00 UTC